The FDA last week confirmed that it would suspend the release of complete response letters pending the resolution of a citizen petition from an unnamed pharma company. Nevertheless, 14 new CRLs are ...
An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, ...
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
With the latest layoffs, Novartis expects to let go of around 800 employees by the end of 2028. More than half of the cuts ...
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates. GSK ...
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the ...
Beautiful, easy data visualization and storytelling The FDA greenlit 26 novel therapies in the first half of 2026, including four for cancer and six for orphan indications. Meanwhile, AstraZeneca and ...
Vertex Pharamceuticals shocked analysts this week with the biggest M&A deal in the company’s history. The cystic fibrosis drugmaker is buying Crinetics Pharmaceuticals for $10 billion, notching one of ...
In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered ...
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace. In the first half of 2026, the major theme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results